600521 华海药业
已收盘 07-03 15:00:00
资讯
新帖
简况
华海药业最新公告:重酒石酸间羟胺注射液获药品注册证书
证券之星 · 07-02 17:51
华海药业最新公告:重酒石酸间羟胺注射液获药品注册证书
华海药业(600521)披露可转换公司债券转股结果暨股份变动公告,7月1日股价上涨2.99%
证券之星 · 07-01 22:25
华海药业(600521)披露可转换公司债券转股结果暨股份变动公告,7月1日股价上涨2.99%
每周股票复盘:华海药业(600521)冲回负债增利8200万元
证券之星 · 06-28
每周股票复盘:华海药业(600521)冲回负债增利8200万元
华海药业(600521)披露关于授权择机出售公司金融资产的公告,6月26日股价下跌3.98%
证券之星 · 06-26
华海药业(600521)披露关于授权择机出售公司金融资产的公告,6月26日股价下跌3.98%
华海药业(600521.SH)子公司HB0017注射液上市许可申请获得受理
智通财经 · 06-25
华海药业(600521.SH)子公司HB0017注射液上市许可申请获得受理
华海药业(600521)披露仲裁案件进展公告,6月24日股价上涨0.2%
证券之星 · 06-24
华海药业(600521)披露仲裁案件进展公告,6月24日股价上涨0.2%
每周股票复盘:XD华海药(600521)华海药业获三款药品注册证
证券之星 · 06-20
每周股票复盘:XD华海药(600521)华海药业获三款药品注册证
华海药业最新公告:获得甲苯磺酸艾多沙班片等三项药品注册证书
证券之星 · 06-15
华海药业最新公告:获得甲苯磺酸艾多沙班片等三项药品注册证书
华海药业最新公告:获得艾拉莫德片药品注册证书
证券之星 · 06-08
华海药业最新公告:获得艾拉莫德片药品注册证书
华海药业(600521)股东周明华质押1300万股,占总股本0.87%
证券之星 · 06-05
华海药业(600521)股东周明华质押1300万股,占总股本0.87%
医保局发布医保目录调整方案;内蒙古检查售卖集采药违规药店
21世纪经济报道 · 06-01
医保局发布医保目录调整方案;内蒙古检查售卖集采药违规药店
华海药业(600521.SH):布瑞哌唑片和注射用硫酸艾沙康唑获得药品注册证书
智通财经 · 05-29
华海药业(600521.SH):布瑞哌唑片和注射用硫酸艾沙康唑获得药品注册证书
每周股票复盘:华海药业(600521)华海转债转股价格下修至16.60元
证券之星 · 05-24
每周股票复盘:华海药业(600521)华海转债转股价格下修至16.60元
华海药业(600521)披露2025年年度股东会决议公告,5月22日股价下跌3.53%
中金财经 · 05-22
华海药业(600521)披露2025年年度股东会决议公告,5月22日股价下跌3.53%
华海药业(600521)披露关于募集资金账户注销的公告,5月21日股价上涨2.22%
证券之星 · 05-21
华海药业(600521)披露关于募集资金账户注销的公告,5月21日股价上涨2.22%
每周股票复盘:华海药业(600521)拟每股派息0.1元
证券之星 · 05-17
每周股票复盘:华海药业(600521)拟每股派息0.1元
华海药业(600521)披露2025年年度股东会资料,5月14日股价下跌2.24%
证券之星 · 05-14
华海药业(600521)披露2025年年度股东会资料,5月14日股价下跌2.24%
5月11日华海药业涨6.14%,兴业医疗保健混合A基金重仓该股
证券之星 · 05-11
5月11日华海药业涨6.14%,兴业医疗保健混合A基金重仓该股
华海药业公布国际专利申请:“5-取代吲哚啉手性胺、其制备方法及其在赛洛多辛的制备中的应用”
证券之星 · 05-02
华海药业公布国际专利申请:“5-取代吲哚啉手性胺、其制备方法及其在赛洛多辛的制备中的应用”
华海药业(600521)2026年一季报简析:净利润同比增长35.9%
证券之星 · 05-01
华海药业(600521)2026年一季报简析:净利润同比增长35.9%
加载更多
公司概况
公司名称:
浙江华海药业股份有限公司
所属行业:
医药制造业
上市日期:
2003-03-04
主营业务:
浙江华海药业股份有限公司的主营业务是多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。公司的主要产品是厄贝沙坦氢氯噻嗪片、氯沙坦钾片、厄贝沙坦片、利伐沙班片、安立生坦片、缬沙坦氢氯噻嗪片、缬沙坦氨氯地平片、缬沙坦片、福辛普利钠片、盐酸舍曲林片、奥氮平片、盐酸帕罗西汀片、草酸艾司西酞普兰片、盐酸多奈哌齐片、磷酸奥司他韦胶囊、伏立康唑片、依非韦伦片。
发行价格:
15.55
{"stockData":{"symbol":"600521","market":"SH","secType":"STK","nameCN":"华海药业","latestPrice":15.41,"timestamp":1783062000000,"preClose":14.91,"halted":0,"volume":30758571,"delay":0,"changeRate":0.0335,"floatShares":1497000000,"shares":1497000000,"eps":0.2493,"marketStatus":"已收盘","change":0.5,"latestTime":"07-03 15:00:00","open":15.12,"high":15.49,"low":14.9,"amount":467000000,"amplitude":0.0396,"askPrice":15.41,"askSize":548,"bidPrice":15.4,"bidSize":318,"shortable":0,"etf":0,"ttmEps":0.2493,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"adjPreClose":14.91,"symbolType":"stock","openAndCloseTimeList":[[1783042200000,1783049400000],[1783054800000,1783062000000]],"highLimit":16.4,"lowLimit":13.42,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1497252196,"isCdr":false,"pbRate":2.4,"roa":"--","peRate":61.813077,"roe":"4.19%","epsLYR":0.18,"committee":-0.538632,"marketValue":23073000000,"turnoverRate":0.0205,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-07-06。","floatMarketCap":23073000000},"requestUrl":"/m/hq/s/600521","defaultTab":"news","newsList":[{"id":"2648066795","title":"华海药业最新公告:重酒石酸间羟胺注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2648066795","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648066795?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:51","pubTimestamp":1782985864,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称,公司近日收到国家药监局核准签发的重酒石酸间羟胺注射液的《药品注册证书》。该药品用于防治低血压,按化学药品3类批准生产可视同通过一致性评价。2025年该药品国内市场销售金额约4.04亿元,公司研发投入约598万元。此次获批进一步丰富了公司产品线,有助于提升市场竞争力。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200030661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521","BK0188","BK0185","BK0028","BK0070","BK0201","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648806541","title":"华海药业(600521)披露可转换公司债券转股结果暨股份变动公告,7月1日股价上涨2.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648806541","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648806541?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:25","pubTimestamp":1782915918,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘,华海药业报收于14.83元,较前一交易日上涨2.99%,最新总市值为222.04亿元。近日,华海药业发布《可转换公司债券转股结果暨股份变动公告》。2026年第二季度期间,共1,000元华海转债转股,形成60股股份。截至2026年6月30日,尚未转股的可转债金额为1,842,381,000元,占发行总额的99.9881%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0201","BK0028","BK0012","600521","BK0185","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646131393","title":"每周股票复盘:华海药业(600521)冲回负债增利8200万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2646131393","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646131393?lang=zh_cn&edition=full","pubTime":"2026-06-28 02:24","pubTimestamp":1782584652,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘,华海药业报收于14.01元,较上周的14.35元下跌2.37%。本周,华海药业6月24日盘中最高价报15.12元。公司公告汇总:股东周明华解除质押2550万股,当前累计质押占总股本3.01%。公司公告汇总浙江华海药业股份有限公司收到山德士支付的7,045,930.69美元,用于补偿公司因仲裁产生的律师费、仲裁费等支出。公司冲回预计负债4,847万元人民币,预计增加2026年度净利润约8,200万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0012","BK0028","BK0201","600521","BK0185","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646336582","title":"华海药业(600521)披露关于授权择机出售公司金融资产的公告,6月26日股价下跌3.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646336582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646336582?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:28","pubTimestamp":1782484100,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘,华海药业报收于14.01元,较前一交易日下跌3.98%,最新总市值为209.77亿元。近日,浙江华海药业股份有限公司召开第九届董事会第十三次临时会议,审议通过《关于授权择机出售公司金融资产的议案》。董事会授权经营管理层在符合规定条件下择机出售公司所持相关金融资产。授权期限内,交易金额或产生的净利润达到披露标准时将及时履行信息披露义务。本次授权有效期为自董事会审议通过之日起12个月内。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600045695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0185","BK0188","BK0012","BK0239","BK0201","600521","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646768798","title":"华海药业(600521.SH)子公司HB0017注射液上市许可申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2646768798","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646768798?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:22","pubTimestamp":1782379348,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华海药业(600521.SH)发布公告,近日,公司下属子公司上海华奥泰生物药业股份有限公司(简称“华奥泰”)收到国家药品监督管理局签发的HB0017注射液境内生产药品注册上市许可申请的《受理通知书》。申报适应症:用于治疗适合接受系统治疗或光疗的中度至重度斑块状银屑病成人患者。HB0017注射液是华奥泰自主研发的以白介素-17A(IL-17A)为靶点的单克隆抗体,拟用于治疗中重度斑块状银屑病(境内注册上市申请已受理)、强直性脊柱炎(推进III期临床)及其他自身免疫疾病。截至目前,公司在HB0017注射液项目上的研发投入合计约人民币45,403万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0070","BK0028","BK0201","BK0185","BK0239","IPOS","BK0188","600521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645899055","title":"华海药业(600521)披露仲裁案件进展公告,6月24日股价上涨0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645899055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645899055?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:48","pubTimestamp":1782294510,"startTime":"0","endTime":"0","summary":"截至2026年6月24日收盘,华海药业报收于14.72元,较前一交易日上涨0.2%,最新总市值为220.4亿元。浙江华海药业股份有限公司于2026年6月24日发布《关于公司涉及仲裁案件的进展公告》。公告显示,公司收到山德士支付的7,045,930.69美元,系国际商会仲裁院裁决其承担公司为应对仲裁所支出的律师费、仲裁费等费用。本次仲裁案原由山德士因缬沙坦原料药杂质问题提起,仲裁庭裁定公司无需承担违约责任,并驳回山德士的全部请求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400033163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0188","BK0185","600521","BK0070","BK0239","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644632250","title":"每周股票复盘:XD华海药(600521)华海药业获三款药品注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2644632250","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644632250?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:25","pubTimestamp":1781893512,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,XD华海药报收于14.35元,较上周的14.45元下跌0.69%。本周,XD华海药6月15日盘中最高价报14.75元。本周关注点公司公告汇总:华海药业及子公司获甲苯磺酸艾多沙班片等三款药品注册证书。公司公告汇总浙江华海药业股份有限公司及下属子公司浙江华海制药科技有限公司近日收到国家药监局核准签发的甲苯磺酸艾多沙班片、培哚普利氨氯地平片、雷米普利片的《药品注册证书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000692.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521","BK0201","BK0239","BK0185","BK0188","BK0070","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643272124","title":"华海药业最新公告:获得甲苯磺酸艾多沙班片等三项药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2643272124","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643272124?lang=zh_cn&edition=full","pubTime":"2026-06-15 18:10","pubTimestamp":1781518259,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称,公司及下属全资子公司制药科技近日收到国家药监局核准签发的甲苯磺酸艾多沙班片、培哚普利氨氯地平片(III)、雷米普利片的《药品注册证书》。上述产品按化学药品4类批准生产可视同通过一致性评价,进一步丰富了公司产品线,有助于提升市场竞争力。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500023889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","600521","BK0185","BK0239","BK0188","BK0012","BK0201","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641604483","title":"华海药业最新公告:获得艾拉莫德片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2641604483","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641604483?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:58","pubTimestamp":1780912689,"startTime":"0","endTime":"0","summary":"华海药业(600521.SH)公告称,公司近日收到国家药监局核准签发的艾拉莫德片《药品注册证书》。该药品用于治疗活动性类风湿关节炎,按化学药品4类批准生产视同通过一致性评价。该产品获批将进一步丰富公司产品线,提升市场竞争力。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800024776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0012","600521","BK0201","BK0239","BK0070","BK0028","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641213169","title":"华海药业(600521)股东周明华质押1300万股,占总股本0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2641213169","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641213169?lang=zh_cn&edition=full","pubTime":"2026-06-05 00:22","pubTimestamp":1780590149,"startTime":"0","endTime":"0","summary":"证券之星消息,华海药业6月5日公开信息显示,股东周明华向上海农村商业银行股份有限公司浦东分行合计质押1300.0万股,占总股本0.87%。质押详情见下表:截止本公告日,股东周明华已累计质押股份7050.0万股,占其持股总数的31.41%。华海药业主营业务:多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500000032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","BK0201","600521","BK0239","BK0185","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981365","title":"医保局发布医保目录调整方案;内蒙古检查售卖集采药违规药店","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981365","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640981365?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:01","pubTimestamp":1780272073,"startTime":"0","endTime":"0","summary":"药械审批国家医保局发布2026年国家医保目录调整工作方案5月31日,国家医保局发布《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整申报指南》《谈判药品续约规则》以及《非独家药品竞价规则》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013755285483.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013755285483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0070","600521","600196","BK0187","301263","BK0188","BK0028","BK0114","BK0012","600513","BK0196","BK0175","BK0185","BK0216","BK0251","300562","IPOS","301096","BK0239","BK0201","BK0250","BK0096","BK0060","BK0183","BK0109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639250746","title":"华海药业(600521.SH):布瑞哌唑片和注射用硫酸艾沙康唑获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2639250746","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639250746?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:43","pubTimestamp":1780047785,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华海药业(600521.SH)发布公告,公司于近日收到国家药品监督管理局核准签发的布瑞哌唑片和注射用硫酸艾沙康唑的《药品注册证书》。根据国家相关政策,公司布瑞哌唑片和注射用硫酸艾沙康唑按化学药品4类批准生产可视同通过一致性评价。上述产品的获批进一步丰富了公司的产品线,有助于提升公司产品的市场竞争力。据悉,布瑞哌唑片用于治疗成人精神分裂症。注射用硫酸艾沙康唑用于成人侵袭性曲霉病和侵袭性毛霉病感染患者的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","BK0028","BK0201","BK0070","BK0185","BK0012","600521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637170378","title":"每周股票复盘:华海药业(600521)华海转债转股价格下修至16.60元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637170378","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637170378?lang=zh_cn&edition=full","pubTime":"2026-05-24 01:38","pubTimestamp":1779557891,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘,华海药业报收于16.42元,较上周的16.52元下跌0.61%。华海转债于2026年5月22日停止转股,5月25日起恢复转股。浙江华海药业股份有限公司公告,因公司股价在连续三十个交易日内有十五个交易日低于当期转股价格的80%,触发“华海转债”转股价格向下修正条款。浙江华海药业股份有限公司于2026年5月21日召开2025年年度股东大会,审议通过向下修正“华海转债”转股价格的议案,并授权董事会办理相关事宜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0239","BK0201","BK0028","BK0188","600521","BK0012","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637831334","title":"华海药业(600521)披露2025年年度股东会决议公告,5月22日股价下跌3.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637831334","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637831334?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:02","pubTimestamp":1779444146,"startTime":"0","endTime":"0","summary":"公司于近日披露《浙江华海药业股份有限公司2025年年度股东会决议公告》。公告显示,公司于2026年5月21日召开2025年年度股东会,审议通过了《公司2025年度董事会工作报告》《公司2025年度利润分配方案》《公司2025年年度报告及其摘要》等18项议案。所有议案均获通过,无否决议案。会议召集召开程序合法,表决结果有效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260522/32247377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["600521","BK0028","BK0070","BK0188","BK0239","BK0012","BK0185","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637986381","title":"华海药业(600521)披露关于募集资金账户注销的公告,5月21日股价上涨2.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637986381","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637986381?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:47","pubTimestamp":1779356865,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘,华海药业报收于17.02元,较前一交易日上涨2.22%,最新总市值为254.83亿元。该股当日开盘16.61元,最高17.65元,最低16.61元,成交额达11.02亿元,换手率为4.28%。浙江华海药业股份有限公司于2026年5月21日发布《关于募集资金账户注销的公告》。存放于工行临海支行的募集资金专户资金已使用完毕,现对该账户予以注销,相关《募集资金专户四方监管协议》相应终止。本次账户注销后,公司2020年可转债募集资金所有专用账户均已全部注销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100032991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","600521","BK0201","BK0070","BK0185","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636770064","title":"每周股票复盘:华海药业(600521)拟每股派息0.1元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636770064","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636770064?lang=zh_cn&edition=full","pubTime":"2026-05-17 03:50","pubTimestamp":1778961022,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,华海药业报收于16.52元,较上周的16.45元上涨0.43%。本周,华海药业5月11日盘中最高价报17.67元。浙江华海药业股份有限公司将于2026年5月21日召开2025年年度股东会,会议采取现场投票与网络投票相结合方式,股权登记日为2026年5月14日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0201","BK0239","BK0070","BK0012","600521","BK0188","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635659745","title":"华海药业(600521)披露2025年年度股东会资料,5月14日股价下跌2.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635659745","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635659745?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:15","pubTimestamp":1778768122,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘,华海药业报收于16.57元,较前一交易日下跌2.24%,最新总市值为248.09亿元。该股当日开盘17.0元,最高17.02元,最低16.52元,成交额达4.06亿元,换手率为1.63%。公司2025年实现营业收入85.87亿元,净利润2.66亿元,拟每股派发现金红利0.1元(含税)。同时提议变更部分募集资金用途,用于建设年产8000kg索马鲁肽中间体项目并永久补充流动资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400042866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","600521","BK0201","BK0012","BK0188","BK0070","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409333","title":"5月11日华海药业涨6.14%,兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409333","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409333?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:24","pubTimestamp":1778487892,"startTime":"0","endTime":"0","summary":"证券之星消息,5月11日华海药业涨6.14%创60日新高,收盘报17.46元,换手率4.75%,成交量71.13万手,成交额12.16亿元。重仓华海药业的公募基金请见下表:该股最近90天内共有4家机构给出评级,买入评级3家,增持评级1家;过去90天内机构目标均价为21.3。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0070","BK0185","BK0201","BK0012","BK0188","BK0239","600521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623508","title":"华海药业公布国际专利申请:“5-取代吲哚啉手性胺、其制备方法及其在赛洛多辛的制备中的应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632623508?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:59","pubTimestamp":1777672752,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示华海药业(600521)公布了一项国际专利申请,专利名为“5-取代吲哚啉手性胺、其制备方法及其在赛洛多辛的制备中的应用”,专利申请号为PCT/CN2024/126359,国际公布日为2026年4月30日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来华海药业已公布的国际专利申请5个,较去年同期增加了25%。结合公司2025年年报财务数据,2025年公司在研发方面投入了12.29亿元,同比增24.57%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521","BK0188","BK0028","BK0012","BK0185","BK0201","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632667694","title":"华海药业(600521)2026年一季报简析:净利润同比增长35.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632667694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632667694?lang=zh_cn&edition=full","pubTime":"2026-05-01 06:11","pubTimestamp":1777587075,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期华海药业发布2026年一季报。根据财报显示,华海药业净利润同比增长35.9%。截至本报告期末,公司营业总收入23.35亿元,同比下降1.4%,归母净利润4.04亿元,同比上升35.9%。持有华海药业最多的基金为兴业医疗保健混合A,目前规模为2.41亿元,最新净值0.8161,较上一交易日上涨0.54%,近一年上涨23.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050100004578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600521"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783163339175,"stockEarnings":[{"period":"1week","weight":0.0999},{"period":"1month","weight":0.011},{"period":"3month","weight":-0.0228},{"period":"6month","weight":-0.0856},{"period":"1year","weight":-0.2856},{"period":"ytd","weight":-0.0856}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0421},{"period":"6month","weight":0.0188},{"period":"1year","weight":0.1683},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江华海药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"89340人(较上一季度增加8.11%)","perCapita":"16759股","listingDate":"2003-03-04","address":"浙江省台州市临海市汛桥镇汛大路88号","registeredCapital":"149725万元","survey":" 浙江华海药业股份有限公司的主营业务是多剂型的仿制药、生物药、创新药及特色原料药的研发、生产和销售。公司的主要产品是厄贝沙坦氢氯噻嗪片、氯沙坦钾片、厄贝沙坦片、利伐沙班片、安立生坦片、缬沙坦氢氯噻嗪片、缬沙坦氨氯地平片、缬沙坦片、福辛普利钠片、盐酸舍曲林片、奥氮平片、盐酸帕罗西汀片、草酸艾司西酞普兰片、盐酸多奈哌齐片、磷酸奥司他韦胶囊、伏立康唑片、依非韦伦片。","listedPrice":15.55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华海药业,600521,华海药业股票,华海药业股票老虎,华海药业股票老虎国际,华海药业行情,华海药业股票行情,华海药业股价,华海药业股市,华海药业股票价格,华海药业股票交易,华海药业股票购买,华海药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华海药业(600521)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华海药业(600521)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}